Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors
March 28, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Proven leader with 36 years of experience with Johnson & Johnson in numerous executive capacities, most recently as Head of Enterprise Supply Chain- Dr. Shetty was instrumental in establishing...
Actinium Pharmaceuticals to Present at 29th Annual ROTH Conference
March 07, 2017 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology Platform
February 28, 2017 07:00 ET
|
Actinium Pharmaceuticals
Allowed patent application claims methods for generating radioimmunoconjugates linked to Actinium-225 Patent expected to expire in July 2030 NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) --...
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
February 21, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Industry veteran to lead development of optimized programs for Iomab-B including initiatives targeted at patients, physicians and payors designed to support clinical development and...
Actinium Pharmaceuticals to Present at Source Capital Group’s 2017 Disruptive Growth & Healthcare Conference
February 13, 2017 16:15 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting
December 05, 2016 13:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today...
Patient Advocate Foundation Launches Transportation Grant for Multiple Myeloma Patients
April 04, 2016 09:09 ET
|
Patient Advocate Foundation
HAMPTON, Va., April 4, 2016 (GLOBE NEWSWIRE) -- In 2015, Patient Advocate Foundation (PAF) found that 15% of patients assisted by their case management department reported access to care issues due to...
Cellectar Biosciences Announces Positive Data From Phase 1 Therapeutic Trial of CLR 131 in Multiple Myeloma
January 05, 2016 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces data from the first cohort of patients...
Multiple myeloma patients with financial burdens are over twice as likely to be at risk for depression, study finds
December 07, 2015 13:21 ET
|
Cancer Support Community
WASHINGTON, Dec. 7, 2015 (GLOBE NEWSWIRE) -- People with multiple myeloma who are experiencing financial burdens due to their cancer situation are almost two and a half times more likely to be at risk...
Rhizen Pharmaceuticals S.A. to present preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in Multiple Myeloma
November 18, 2014 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a poster presentation for
RP6530, a novel dual PI3K delta/gamma inhibitor in Multiple
Myeloma.
...